Leerink Partners analyst Mani Foroohar upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $53 to $62.
Leerink Partners Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $62
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.